Cytomegalovirus-specific CD8 T cells kill B16 melanoma cells in vivo when activated by bifunctional major histocompatibility class I - antibody fusion molecules (pMHCI-IgGs).

Abstract

Bispecific antibodies (BiAb), some of which simultaneously bind to tumor-associated antigens on tumors and activate the CD3 receptor of T cells, have shown promising results in both pre-clinical models and clinical trials. However, widespread activation of T cells can result in toxicity, while sometimes still failing to control or eradicate tumors. A… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.